10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer
Background The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized prostate ca...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2016
|
| _version_ | 1797105421695057920 |
|---|---|
| author | Hamdy, F Donovan, J Lane, J Mason, M Metcalfe, C Holding, P Davis, M Peters, T Turner, E Martin, R Oxley, J Robinson, M Staffurth, J Walsh, E Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Paul, A Powell, P Prescott, S Rosario, D Rowe, E Neal, D |
| author_facet | Hamdy, F Donovan, J Lane, J Mason, M Metcalfe, C Holding, P Davis, M Peters, T Turner, E Martin, R Oxley, J Robinson, M Staffurth, J Walsh, E Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Paul, A Powell, P Prescott, S Rosario, D Rowe, E Neal, D |
| author_sort | Hamdy, F |
| collection | OXFORD |
| description | Background The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized prostate cancer. Between 1999 and 2009, a total of 82,429 men 50 to 69 years of age received a PSA test; 2664 received a diagnosis of localized prostate cancer, and 1643 agreed to undergo randomization to active monitoring (545 men), surgery (553), or radiotherapy (545). The primary outcome was prostate-cancer mortality at a median of 10 years of follow-up. Secondary outcomes included the rates of disease progression, metastases, and all-cause deaths. Results There were 17 prostate-cancer-specific deaths overall: 8 in the active-monitoring group (1.5 deaths per 1000 person-years; 95% confidence interval [CI], 0.7 to 3.0), 5 in the surgery group (0.9 per 1000 person-years; 95% CI, 0.4 to 2.2), and 4 in the radiotherapy group (0.7 per 1000 person-years; 95% CI, 0.3 to 2.0); the difference among the groups was not significant (P=0.48 for the overall comparison). In addition, no significant difference was seen among the groups in the number of deaths from any cause (169 deaths overall; P=0.87 for the comparison among the three groups). Metastases developed in more men in the active-monitoring group (33 men; 6.3 events per 1000 person-years; 95% CI, 4.5 to 8.8) than in the surgery group (13 men; 2.4 per 1000 person-years; 95% CI, 1.4 to 4.2) or the radiotherapy group (16 men; 3.0 per 1000 person-years; 95% CI, 1.9 to 4.9) (P=0.004 for the overall comparison). Higher rates of disease progression were seen in the active-monitoring group (112 men; 22.9 events per 1000 person-years; 95% CI, 19.0 to 27.5) than in the surgery group (46 men; 8.9 events per 1000 person-years; 95% CI, 6.7 to 11.9) or the radiotherapy group (46 men; 9.0 events per 1000 person-years; 95% CI, 6.7 to 12.0) (P<0.001 for the overall comparison). Conclusions At a median of 10 years, prostate-cancer-specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments. Surgery and radiotherapy were associated with lower incidences of disease progression and metastases than was active monitoring. (Funded by the National Institute for Health Research; Current Controlled Trials number, ISRCTN20141297 ; ClinicalTrials.gov number, NCT02044172 .). |
| first_indexed | 2024-03-07T06:47:19Z |
| format | Journal article |
| id | oxford-uuid:fb4ec762-82d1-42e4-9e8f-7f812d5b5b99 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:47:19Z |
| publishDate | 2016 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:fb4ec762-82d1-42e4-9e8f-7f812d5b5b992022-03-27T13:13:00Z10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fb4ec762-82d1-42e4-9e8f-7f812d5b5b99EnglishSymplectic Elements at OxfordMassachusetts Medical Society2016Hamdy, FDonovan, JLane, JMason, MMetcalfe, CHolding, PDavis, MPeters, TTurner, EMartin, ROxley, JRobinson, MStaffurth, JWalsh, EBollina, PCatto, JDoble, ADoherty, AGillatt, DKockelbergh, RKynaston, HPaul, APowell, PPrescott, SRosario, DRowe, ENeal, DBackground The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized prostate cancer. Between 1999 and 2009, a total of 82,429 men 50 to 69 years of age received a PSA test; 2664 received a diagnosis of localized prostate cancer, and 1643 agreed to undergo randomization to active monitoring (545 men), surgery (553), or radiotherapy (545). The primary outcome was prostate-cancer mortality at a median of 10 years of follow-up. Secondary outcomes included the rates of disease progression, metastases, and all-cause deaths. Results There were 17 prostate-cancer-specific deaths overall: 8 in the active-monitoring group (1.5 deaths per 1000 person-years; 95% confidence interval [CI], 0.7 to 3.0), 5 in the surgery group (0.9 per 1000 person-years; 95% CI, 0.4 to 2.2), and 4 in the radiotherapy group (0.7 per 1000 person-years; 95% CI, 0.3 to 2.0); the difference among the groups was not significant (P=0.48 for the overall comparison). In addition, no significant difference was seen among the groups in the number of deaths from any cause (169 deaths overall; P=0.87 for the comparison among the three groups). Metastases developed in more men in the active-monitoring group (33 men; 6.3 events per 1000 person-years; 95% CI, 4.5 to 8.8) than in the surgery group (13 men; 2.4 per 1000 person-years; 95% CI, 1.4 to 4.2) or the radiotherapy group (16 men; 3.0 per 1000 person-years; 95% CI, 1.9 to 4.9) (P=0.004 for the overall comparison). Higher rates of disease progression were seen in the active-monitoring group (112 men; 22.9 events per 1000 person-years; 95% CI, 19.0 to 27.5) than in the surgery group (46 men; 8.9 events per 1000 person-years; 95% CI, 6.7 to 11.9) or the radiotherapy group (46 men; 9.0 events per 1000 person-years; 95% CI, 6.7 to 12.0) (P<0.001 for the overall comparison). Conclusions At a median of 10 years, prostate-cancer-specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments. Surgery and radiotherapy were associated with lower incidences of disease progression and metastases than was active monitoring. (Funded by the National Institute for Health Research; Current Controlled Trials number, ISRCTN20141297 ; ClinicalTrials.gov number, NCT02044172 .). |
| spellingShingle | Hamdy, F Donovan, J Lane, J Mason, M Metcalfe, C Holding, P Davis, M Peters, T Turner, E Martin, R Oxley, J Robinson, M Staffurth, J Walsh, E Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Paul, A Powell, P Prescott, S Rosario, D Rowe, E Neal, D 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer |
| title | 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer |
| title_full | 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer |
| title_fullStr | 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer |
| title_full_unstemmed | 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer |
| title_short | 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer |
| title_sort | 10 year outcomes after monitoring surgery or radiotherapy for localized prostate cancer |
| work_keys_str_mv | AT hamdyf 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT donovanj 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT lanej 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT masonm 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT metcalfec 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT holdingp 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT davism 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT peterst 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT turnere 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT martinr 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT oxleyj 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT robinsonm 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT staffurthj 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT walshe 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT bollinap 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT cattoj 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT doblea 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT dohertya 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT gillattd 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT kockelberghr 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT kynastonh 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT paula 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT powellp 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT prescotts 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT rosariod 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT rowee 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer AT neald 10yearoutcomesaftermonitoringsurgeryorradiotherapyforlocalizedprostatecancer |